By McGuire Woods LLP
Original Source: jdsupra.com
The COVID-19 pandemic is likely to have profound impacts on people with opioid use disorder (OUD) and other drug use disorders. Generally, opioid agonist therapies such as methadone and buprenorphine require patients to gather in large groups and attend frequent in-person visits with prescribers. Public health interventions designed to mitigate the spread of COVID-19 can severely impact the ability of patients with OUD to access opioid agonist therapy and to use drugs safely.
The Substance Abuse and Mental Health Services Administration (SAMHSA) published new guidance for the care and treatment of mental and substance use disorders during the COVID-19 outbreak. This guidance includes…click here to continue reading